Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Topical delgocitinib for facial vitiligo

A legfontosabb adatok

Ki végzi
Gentofte Hospital
Hol
Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
12 fő, tervezett
Kezdés
2026. márc. 25.
Várható befejezés
2028. jan. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. szeptember 24.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Able to provide written informed consent
  • Age 18 years or above at screening
  • Ability to understand, speak, and read Danish, as assessed by the investigator
  • Have a clinical diagnosis of non-segmental vitiligo with facial involvement corresponding to at least 0.5% of total BSA
  • Agree not to use any other agent used to treat vitiligo from screening through the final visit (also please see Exclusion criteria 9─16)
  • Able and willing to follow trial procedures including application of trial medication to facial vitiligo lesions
  • A WOCBP must agree to use an acceptable method of birth control throughout the trial up until the last application of the trial treatment

Ki nem vehet részt

  • Treatment with any marketed biological therapy or investigational biologic agents within 12 weeks or 5-lives, whichever is longer, prior to baseline
  • Systemic treatment with immunosuppressive or immunomodulating drugs within 12 weeks prior to baseline
  • Use of tanning beds, phototherapy, or intentional UV exposure within 12 weeks prior to baseline
  • Cutaneous applied treatment with topical corticosteroids or other immunomodulators such as phosphodiesterase type 4 inhibitors or calcineurin inhibitors within four weeks prior to baseline
  • Any systemic or topical therapies that could increase the skin sensitivity to UV/visible light or impact skin pigmentation, that is, retinoids, tetracyclines within four weeks prior to baseline
  • Surgical or laser treatments in the facial area within 12 weeks prior to baseline
  • Any significant illness or medical, physical, or psychiatric condition that, in the opinion of the investigator, could hinder the participant’s ability to fully engage in the study—such as receiving the trial medication or attending scheduled visits—pose a notable risk to their health, or compromise the integrity of the trial data
  • Concurrent skin diseases in the face
  • Clinically significant bacterial, viral, or fungal skin infection in the face within one week before baseline
  • Previous or current treatment with JAK inhibitors (including delgocitinib), systemic or topical
  • Disease duration of more than 10 years in the area chosen for treatment
  • History of any known primary immunodeficiency disorder
  • Any unstable disorder that could affect the safety of the patient throughout the trial or impede the patient’s ability to complete the trial
  • Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator
  • Other active skin diseases requiring medical treatment
  • Other forms of vitiligo (e.g., segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g., piebaldism, pityriasis alba, leprosy, post inflammatory hypopigmentation, progressive macule hypomelanosis, idiopathic guttate hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor)
  • Known or suspected hypersensitivity to any components of the trial drug
  • History of cancer (for skin cancer in the facial area, the patient is NOT eligible; for skin cancer outside of the facial area, a patient is eligible if in remission and curative therapy has been completed ≥12 months prior to screening; for other malignancies, a patient is eligible if in remission and curative therapy has been completed ≥5 years prior to screening)
  • Any depigmentation treatments for past treatment of vitiligo or other pigmented areas
  • Planned hospitalization during the trial period
  • Signs of follicular repigmentation in the area chosen for treatment
  • Any clinically abnormal finding observed during the screening period that could affect the safety of the patient or influence the ability to complete the trial
  • Current participation in any other interventional clinical trial
  • Women who are pregnant or breastfeeding, or women considering pregnancy during the period of their trial participation
  • Patients who have no pigmented hair within any of the vitiligo areas on the face

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This open-label proof-of-concept trial primarily aims to define whether delgocitinib cream is a potential treatment for patients with non-segmental vitiligo in the facial area.

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Open-label proof-of-concept trial of topical delgocitinib in patients with facial vitiligo
A regiszteradat frissítve
2026. szeptember 24.